Manulife announces $13 billion reinsurance deal, including $6 billion of long-term care, with Global Atlantic
Largest ever LTC reinsurance transaction
Major milestone for Manulife's portfolio transformation
Conference call to be held
TSX/NYSE/PSE: MFC SEHK: 945 C$ unless otherwise stated
- Reinsuring
$13 billion of reserves1, including$6 billion , or 14% of total LTC reserves, to Global Atlantic and its partners - Represents largest ever LTC reinsurance transaction
- Ability to transact with leading reinsurance counterparty and its LTC reinsurance partner further validates the prudence of our LTC reserves and assumptions
- Releases
$1.2 billion of capital, which we intend to fully return to shareholders via share buybacks, resulting in core EPS2 and core ROE2 accretion - Attractive earnings multiple of 9.5 times3 and 1.0 times book value multiple4
- Reduces the risk from legacy blocks, including a 12% reduction in LTC morbidity sensitivities5
- Expect to dispose
$1.7 billion of alternative long-duration assets ("ALDA") - Represents a full risk transfer with significant structural protection, and with a highly experienced counterparty and its partners
- A major milestone in reshaping our portfolio with core earnings2 contribution from LTC and variable annuities further reduced to 11%6 from 24% in 20177
- We have received approval from the Office of the Superintendent
of Financial Institutions ("OSFI") to launch a normal course issuer bid ("NCIB") that permits the purchase for cancellation of up to approximately 2.8% of our outstanding common shares commencingFebruary 2024 . The NCIB remains subject to the approval of theToronto Stock Exchange ("TSX").
"This agreement represents the largest LTC reinsurance transaction ever in the insurance industry, and it is a major milestone in our strategy to reshape our portfolio, reduce risk, deliver value to shareholders, and invest in high-potential growth areas of our business. We expect to generate a —
"Manulife has been committed to improving the profitability and risk profile of our inforce business. This deal will reduce our LTC reserves by —
|
We will reinsure a combined
Global
The transaction reduces LTC reserves by
The transaction also further validates our LTC reserves and assumptions. The negative ceding commission associated with the LTC block of
The transaction is expected to release
The transaction is priced at book value and is expected to result in an annual reduction to core earnings of approximately
Global
Subject to the approval of the TSX, Manulife intends to launch a NCIB permitting the purchase for cancellation of up to 50 million of its common shares, representing approximately 2.8% of Manulife's issued and outstanding common shares. As at
Purchases under the NCIB may be made through the facilities of the TSX, the
In addition, Manulife may undertake repurchases of its common shares outside of
Subject to regulatory approval, Manulife intends from time to time to enter into pre-defined plans with a registered investment dealer to allow for the repurchase of common shares at times when Manulife ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules or otherwise. Any such plans will be adopted in accordance with applicable Canadian securities laws and
Manulife's most recent normal course issuer bid (the "2023 NCIB") commenced on
A live webcast and conference call are scheduled for
To access the conference call, dial 1-800-806-5484 or 1-416-340-2217 (Passcode: 7766594#). International dial-in numbers are also available. Please call in 15 minutes prior to the scheduled start time.
Slides related to this announcement are available on the Manulife website.
The archived webcast will be available at manulife.com/en/investors/ following the call.
Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.
FOOTNOTES
All figures and estimates are based on
1. |
IFRS 17 current estimate of present value of future cashflows + risk adjustment + contractual service margin. |
2. |
Core earnings is a Non-GAAP financial measure, and diluted core earnings per common share ("core EPS") and core ROE are Non-GAAP ratios. See "Performance and Non-GAAP measures" below and in our Third Quarter 2023 Management's Discussion and Analysis ("3Q23 MD&A") for additional information. |
3. |
Ratio of capital release to annual core earnings impact. |
4. |
Ratio of the market value of assets transferred to the sum of IFRS 17 current estimate of present value of future cash flows + risk adjustment + contractual service margin. |
5. |
Pro forma, post-tax reduction in potential impact on reserves for a 5% adverse change in LTC morbidity assumptions. |
6. |
Pro forma 3Q23 year-to-date. |
7. |
Under IFRS 4. |
8. |
Pro forma. Includes |
Manulife prepares its Consolidated Financial Statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the
From time to time, Manulife makes written and/or oral forward-looking statements, including in this presentation. In addition, our representatives may make forward-looking statements orally to analysts, investors, the media and others. All such statements are made pursuant to the "safe harbour" provisions of Canadian provincial securities laws and the
The forward-looking statements in this document include, but are not limited to, statements with respect to the disposal of ALDA assets, the expected closing time of the reinsurance transactions referred to in this document and their associated capital release and possible share buybacks under a normal course issuer bid and also relate to, among other things, our objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and can generally be identified by the use of words such as "may", "will", "could", "should", "would", "likely", "suspect", "outlook", "expect", "intend", "estimate", "anticipate", "believe", "plan", "forecast", "objective", "seek", "aim", "continue", "goal", "restore", "embark" and "endeavour" (or the negative thereof) and words and expressions of similar import, and include statements concerning possible or assumed future results. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements and they should not be interpreted as confirming market or analysts' expectations in any way.
Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to: general business and economic conditions (including but not limited to the performance, volatility and correlation of equity markets, interest rates, credit and swap spreads, inflation rates, currency rates, investment losses and defaults, market liquidity and creditworthiness of guarantors, reinsurers and counterparties); the ongoing prevalence of COVID-19, including any variants, as well as actions that have been, or may be taken by governmental authorities in response to COVID-19, including the impact of any variants; changes in laws and regulations; changes in accounting standards applicable in any of the territories in which we operate; changes in regulatory capital requirements; our ability to obtain premium rate increases on in-force policies; our ability to execute strategic plans and changes to strategic plans; downgrades in our financial strength or credit ratings; our ability to maintain our reputation; impairments of goodwill or intangible assets or the establishment of provisions against future tax assets; the amount of contractual service margin recognized for service provided; the accuracy of estimates relating to morbidity, mortality and policyholder behaviour; the accuracy of other estimates used in applying accounting policies, actuarial methods and embedded value methods; our ability to implement effective hedging strategies and unforeseen consequences arising from such strategies; our ability to source appropriate assets to back our long-dated liabilities; level of competition and consolidation; our ability to market and distribute products through current and future distribution channels; unforeseen liabilities or asset impairments arising from acquisitions and dispositions of businesses; the realization of losses arising from the sale of investments classified as fair value through other comprehensive income; our liquidity, including the availability of financing to satisfy existing financial liabilities on expected maturity dates when required; obligations to pledge additional collateral; the availability of letters of credit to provide capital management flexibility; accuracy of information received from counterparties and the ability of counterparties to meet their obligations; the availability, affordability and adequacy of reinsurance; legal and regulatory proceedings, including tax audits, tax litigation or similar proceedings; our ability to adapt products and services to the changing market; our ability to attract and retain key executives, employees and agents; the appropriate use and interpretation of complex models or deficiencies in models used; political, legal, operational and other risks associated with our non-North American operations; geopolitical uncertainty, including international conflicts; acquisitions or divestitures, and our ability to complete transactions; environmental concerns, including climate change; our ability to protect our intellectual property and exposure to claims of infringement; and our inability to withdraw cash from subsidiaries and the fact that the amount and timing of any future common share repurchases will depend on the earnings, cash requirements and financial condition of Manulife, market conditions, capital requirements (including under LICAT capital standards), common share issuance requirements, applicable law and regulations (including Canadian and
Additional information about material risk factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in our 3Q23 Management's Discussion and Analysis under "Risk Management and Risk Factors Update" and "Critical Actuarial and Accounting Policies", in our 2022 Management's Discussion and Analysis under "Risk Management and Risk Factors" and "Critical Actuarial and Accounting Policies", and in the "Risk Management" note to the Consolidated Financial Statements in our most recent annual and interim reports and elsewhere in our filings with Canadian and
The forward-looking statements in this presentation are, unless otherwise indicated, stated as of the date hereof and are presented for the purpose of assisting investors and others in understanding our financial position and results of operations, our future operations, as well as our objectives and strategic priorities, and may not be appropriate for other purposes. We do not undertake to update any forward-looking statements, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/manulife-announces-13-billion-reinsurance-deal-including-6-billion-of-long-term-care-with-global-atlantic-302011267.html
SOURCE
Rising Education Spending Is Also Driven by State-Level Problems That Need State-Level Solutions
CyberCube Launches Marginal Risk Analysis Capabilities at the Point of Underwriting With the Latest Account Manager Release
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News